All News
Best of 2023: Treatment and Management of Neuropsychiatric Lupus
At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder.
Read Article
Global temporal trends in MSK disorders in women of childbearing age increasing in138 countries, 24 decreasing & 42 w. flat trends. In 2019, the prevalence was 354 million w/ India, with China, USA, Indonesia & Brazil highest w/ 51% of global prevalence https://t.co/8nn4lTtNU2 https://t.co/BdkR3aXsZO
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: Treatment and Management of Neuropsychiatric Lupus
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus.
https://t.co/0MXAtkDUmQ https://t.co/ZYuLniETnP
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?
https://t.co/9xn7lvxPiG https://t.co/PFYUISEKLe
Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…
Links:
Dr. John Cush RheumNow ( View Tweet)
Could Methotrexate Work in Hand Osteoarthritis? Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis! https://t.co/TnvhGUiWuw https://t.co/FfnC63nBSa
Dr. John Cush RheumNow ( View Tweet)
Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/NwrbdMMdLU https://t.co/eRls0fLMJs
Links:
Dr. John Cush RheumNow ( View Tweet)
Gout Flare Prophylaxis - Colchicine or NSAIDs?
A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout. https://t.co/mZZxTIUeQq https://t.co/43COjhNXUf
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/wOZh9qGQZD https://t.co/ODNcDHp1iU
Links:
Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/gvbPkeq2sH https://t.co/J25U6rWNTy
Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitors Reduce Gout Flares and CV Events. A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/laOh4CsZ8Z https://t.co/6oas9AWc8j
Dr. John Cush RheumNow ( View Tweet)
Are you up-to-date with the relationship between SpA, its comorbidities, and how it impacts patients? Review this update showcasing a present overview of this topic.
Sponsored by Novartis Medical Affairs. https://t.co/zirCeZ0Fgh https://t.co/HIwVNoV94H
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid vasculitis (RV) metanalysis: RV decreased from 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/gBxd9EIvo2 https://t.co/NFMSkeAq5d
Dr. John Cush RheumNow ( View Tweet)
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/n4e564a3gN https://t.co/mnVliEuafK
Dr. John Cush RheumNow ( View Tweet)
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/X5Q1MlmkzW https://t.co/NtbLQv6b2q
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2024 is nearly here!
Among our 25 speakers, Dr. Weber will cover Cardio-Rheumatology Clinic - Identifying CV Risks. Dr. Guma will cover Nutrition in RA. Dr. El Gabalaway will cover the Prevention of RA, all in a session on Success in RA.
https://t.co/5kq9KReEsJ https://t.co/L2GiR8Upqn
Links:
Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/vY1yZUX25S
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: PMR: glad or bad tidings?
“Life was turned upside down overnight” – PMR patient.
https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
https://t.co/QQ2IEEMQVy https://t.co/M4NHkasFz6
Dr. John Cush RheumNow ( View Tweet)